JP2025503546A5 - - Google Patents

Info

Publication number
JP2025503546A5
JP2025503546A5 JP2024539566A JP2024539566A JP2025503546A5 JP 2025503546 A5 JP2025503546 A5 JP 2025503546A5 JP 2024539566 A JP2024539566 A JP 2024539566A JP 2024539566 A JP2024539566 A JP 2024539566A JP 2025503546 A5 JP2025503546 A5 JP 2025503546A5
Authority
JP
Japan
Prior art keywords
cells
car
optionally
hla
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503546A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082431 external-priority patent/WO2023129929A1/en
Publication of JP2025503546A publication Critical patent/JP2025503546A/ja
Publication of JP2025503546A5 publication Critical patent/JP2025503546A5/ja
Pending legal-status Critical Current

Links

JP2024539566A 2021-12-30 2022-12-27 Il-10およびキメラ抗原受容体を発現するcd4+t細胞およびその使用 Pending JP2025503546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295491P 2021-12-30 2021-12-30
US63/295,491 2021-12-30
PCT/US2022/082431 WO2023129929A1 (en) 2021-12-30 2022-12-27 Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025503546A JP2025503546A (ja) 2025-02-04
JP2025503546A5 true JP2025503546A5 (cg-RX-API-DMAC7.html) 2026-01-07

Family

ID=85172951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539566A Pending JP2025503546A (ja) 2021-12-30 2022-12-27 Il-10およびキメラ抗原受容体を発現するcd4+t細胞およびその使用

Country Status (11)

Country Link
US (2) US20250108113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4456927A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503546A (cg-RX-API-DMAC7.html)
KR (1) KR20250005566A (cg-RX-API-DMAC7.html)
CN (1) CN119136843A (cg-RX-API-DMAC7.html)
AR (2) AR128124A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022423984A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244829A1 (cg-RX-API-DMAC7.html)
IL (1) IL313935A (cg-RX-API-DMAC7.html)
TW (1) TW202334400A (cg-RX-API-DMAC7.html)
WO (1) WO2023129929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025235772A1 (en) * 2024-05-09 2025-11-13 Cabaletta Bio, Inc. Methods and compositions for preparing genetically modified immune cells
WO2026015450A1 (en) * 2024-07-06 2026-01-15 Tr1X, Inc. Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
EP4678187A1 (en) * 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026122907A2 (en) * 2024-12-06 2026-06-11 Tr1X, Inc. Polydonor cd4 + t cells expressing il-10 for treatment of crohn's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
AU2014351871B2 (en) * 2013-11-22 2020-02-13 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
ES2900632T3 (es) 2015-03-13 2022-03-17 Fond Telethon Células T CD4+ productoras de IL-10 para uso en el tratamiento de un cáncer
CA2987992A1 (en) * 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
US11365391B2 (en) * 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
CN117298260A (zh) 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
DK3757120T3 (da) 2016-10-04 2022-07-25 Prec Biosciences Inc Co-stimulerende domæner til anvendelse i genetisk modificerede celler
AU2018292181B2 (en) * 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
AU2018309735B2 (en) 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
WO2019077037A1 (en) * 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
JP7097465B2 (ja) * 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
EP3937974A1 (en) 2019-03-11 2022-01-19 Leucid Bio Ltd Muc1 parallel car (pcar) therapeutic agents
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars
EP3980035A4 (en) 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
WO2022005462A1 (en) 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof
CA3228536A1 (en) * 2021-08-24 2023-03-02 Yugang Guo Il-10 expressing cells for enhanced cancer immunotherapies

Similar Documents

Publication Publication Date Title
AU2021221785B2 (en) Engineered gamma delta T-cells
US20230092130A1 (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
JP2024138456A (ja) 改変された制御性t細胞
EP3368075B1 (en) Chimeric antigen receptor molecules and uses thereof
TWI899050B (zh) 通用抗原呈現細胞及其用途
US20250002855A1 (en) Methods for expanding t cells for the treatment of cancer and related malignancies
EP2944652A1 (en) Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
JP2023538012A (ja) 免疫細胞機能の改善
US20240216426A1 (en) Recombinant antigen presenting cells
CN116411025A (zh) Sirt1-7蛋白在免疫治疗中的应用
KR20220038776A (ko) T 세포 수용체 및 이의 사용 방법
WO2023284875A1 (zh) 嵌合抗原受体
CN118510901A (zh) 嵌合衔接子多肽
EP4173640A1 (en) Method for stabilizing binding of antibody to nk cell and use thereof
WO2024193714A1 (zh) 细胞免疫疗法的组合物和方法
WO2024153124A1 (zh) 经修饰的原代t细胞及其用途
JP7856563B2 (ja) がんのt細胞治療のための細胞傷害性エフェクターメモリーt細胞の産生方法
WO2025247380A1 (en) Nkg2d receptor and method of using thereof
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
CN120005830A (zh) 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用
WO2023123225A1 (zh) Sirt1-7蛋白在免疫治疗中的应用
CN121800931A (zh) 靶向cll1的增强型嵌合抗原受体及其应用
HK40085955A (en) Method for stabilizing binding of antibody to nk cell and use thereof
HK1260234B (en) Chimeric antigen receptor molecules and uses thereof
HK1260234A1 (en) Chimeric antigen receptor molecules and uses thereof